AIM ImmunoTech Reports Positive Preliminary Data in Phase 1B/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
aim immunotech報告稱,Ampligen和Imfinzi聯合治療晚期胰腺癌的1B/2期研究初步數據呈積極態勢
AIM ImmunoTech Reports Positive Preliminary Data in Phase 1B/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
aim immunotech報告稱,Ampligen和Imfinzi聯合治療晚期胰腺癌的1B/2期研究初步數據呈積極態勢
譯文內容由第三人軟體翻譯。